Literature DB >> 16474392

Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia.

Joy T Walter1, Karina Alviña, Mary D Womack, Carolyn Chevez, Kamran Khodakhah.   

Abstract

Episodic ataxia type-2 (EA2) is caused by mutations in P/Q-type voltage-gated calcium channels that are expressed at high densities in cerebellar Purkinje cells. Because P/Q channels support neurotransmitter release at many synapses, it is believed that ataxia is caused by impaired synaptic transmission. Here we show that in ataxic P/Q channel mutant mice, the precision of Purkinje cell pacemaking is lost such that there is a significant degradation of the synaptic information encoded in their activity. The irregular pacemaking is caused by reduced activation of calcium-activated potassium (K(Ca)) channels and was reversed by pharmacologically increasing their activity with 1-ethyl-2-benzimidazolinone (EBIO). Moreover, chronic in vivo perfusion of EBIO into the cerebellum of ataxic mice significantly improved motor performance. Our data support the hypothesis that the precision of intrinsic pacemaking in Purkinje cells is essential for motor coordination and suggest that K(Ca) channels may constitute a potential therapeutic target in EA2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474392     DOI: 10.1038/nn1648

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  207 in total

1.  Control of firing patterns through modulation of axon initial segment T-type calcium channels.

Authors:  Kevin J Bender; Victor N Uebele; John J Renger; Laurence O Trussell
Journal:  J Physiol       Date:  2011-11-07       Impact factor: 5.182

2.  Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.

Authors:  Emma M Perkins; Yvonne L Clarkson; Nancy Sabatier; David M Longhurst; Christopher P Millward; Jennifer Jack; Junko Toraiwa; Mitsunori Watanabe; Jeffrey D Rothstein; Alastair R Lyndon; David J A Wyllie; Mayank B Dutia; Mandy Jackson
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

3.  Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.

Authors:  F Woodward Hopf; Jeffrey A Simms; Shao-Ju Chang; Taban Seif; Selena E Bartlett; Antonello Bonci
Journal:  Biol Psychiatry       Date:  2010-12-31       Impact factor: 13.382

4.  Ethanol and vestibular stimulation reveal simple and complex aspects of cerebellar heterogeneity.

Authors:  Leonard M Eisenman
Journal:  Cerebellum       Date:  2011-09       Impact factor: 3.847

5.  KCa channels as therapeutic targets in episodic ataxia type-2.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

6.  The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 7.  Nothing can be coincidence: synaptic inhibition and plasticity in the cerebellar nuclei.

Authors:  Jason R Pugh; Indira M Raman
Journal:  Trends Neurosci       Date:  2009-01-27       Impact factor: 13.837

Review 8.  The cerebellum and migraine.

Authors:  Maurice Vincent; Nouchine Hadjikhani
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

9.  Modulating human procedural learning by cerebellar transcranial direct current stimulation.

Authors:  Roberta Ferrucci; Andre R Brunoni; Marta Parazzini; Maurizio Vergari; Elena Rossi; Manuela Fumagalli; Francesca Mameli; Manuela Rosa; Gaia Giannicola; Stefano Zago; Alberto Priori
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

10.  Cerebellar Purkinje cells control eye movements with a rapid rate code that is invariant to spike irregularity.

Authors:  Hannah L Payne; Ranran L French; Christine C Guo; Td Barbara Nguyen-Vu; Tiina Manninen; Jennifer L Raymond
Journal:  Elife       Date:  2019-05-03       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.